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INTRODUCTION
Graft-versus-host disease (GVHD) is the result of an
intricate immune response to foreign allogeneic stimuli.
GVHD is the process caused by the immunologic response
of donor T cells infused into an allogeneic recipient [1,2],
but removal of T cells that are responsible for GVHD has
been associated with a higher rate of graft failure and relapse
[3-5]. The use of immunosuppressive drugs is another
approach to the prophylaxis of acute GVHD. Many studies
have used combinations of immunosuppressive drugs after
HLA-identical marrow transplantation. The regimen of
methotrexate (MTX) on days 1, 3, 6, and 11, plus a 180-day
course of cyclosporine (CSP) twice a day, was compare d
with either drug used alone [6-9]. The combination regimen
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ABSTRACT
We have previously demonstrated a decrease in the incidence of acute graft-versus-host disease (GVHD) with the
addition of methotrexate (MTX) to cyclosporine (CSP) and prednisone (PSE) chemotherapy in patients with
leukemia. We have now completed a prospective randomized trial comparing the 3-drug regimen (CSP/MTX/PSE,
including 3 doses of MTX) to the standard 2-drug regimen (CSP/MTX, including 4 doses of MTX) to investigate
the benefit of PSE used up front for the prevention of acute and chronic GVHD. In the trial, 193 patients were ran-
domized and 186 were included in the final analysis. All patients received a bone marrow graft from a fully histo-
compatible sibling donor. The pre p a r a t o ry regimen consisted of fractionated total-body irradiation (fTBI) and
etoposide in all but 13 patients, who received fTBI and cyclophosphamide. The patients were randomized to re c e i v e
either CSP/MTX/PSE or CSP/MTX. The 2 groups were well balanced with respect to diagnosis, disease stage, age,
d o n o r- recipient sex, and parity. In an intent-to-treat analysis, the incidence of acute GVHD was 18% (95% confi-
dence interval [CI] 12-28) for the CSP/MTX/PSE group compared with 20% (CI 10-26) for the CSP/MTX gro u p
(P = .60), with a median follow up of 2.2 years. Overall survival was 65% for those receiving CSP/MTX/PSE and
72% for those receiving CSP/MTX (P = .10); the relapse rate was 15% for the CSP/MTX/PSE group and 12% for
the CSP/MTX group (P = .83). The incidence of chronic GVHD was similar (46% versus 52%; P = .38), with a fol-
low-up of 0.7 to 6.0 years. Of interest, 21 patients went off study due to GVHD (5 in the CSP/MTX/PSE group and
16 in the CSP/MTX group [P = .02]), and 11 patients went off study because of alveolar hemorrhage (3 in the
CSP/MTX/PSE group and 8 in the CSP/MTX group [P = .22]). The addition of PSE did not result in a higher inci-
dence of infectious complications, bacterial (66% versus 58%), viral (77% versus 66%), or fungal (20% versus 20%),
in those receiving CSP/MTX/PSE versus CSP/MTX, re s p e c t i v e l y. These data suggest that the addition of PSE was
associated with a somewhat lower incidence of early posttransplantation complications but did not have a positive
impact on the incidence of acute or chronic GVHD or event-free or overall surv i v a l .
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was shown to reduce GVHD and improve survival. This
regimen remains the most widely used for the prophylaxis of
acute GVHD. 
In 1976, we began a series of sequential trials for the pro-
phylaxis of acute GVHD. In a prospective randomized study,
CSP combined with prednisone (PSE) was demonstrated to
reduce the incidence of GVHD from 47% to 28% compare d
with the combination of MTX with PSE [10]. This re g i m e n
was subsequently modified by increasing the dose of PSE and
s t a rting it on day 7 rather than on day 15, resulting in a fur-
ther reduction in the incidence of acute GVHD (K.G.B.,
S . J . F., unpublished data). Based on this encouraging inform a-
tion, we conducted a randomized study to determine whether
the addition of 3 doses of MTX (days 1, 3, and 6) to the CSP
and PSE regimen would further decrease the incidence of
acute GVHD. The results of this prospective study demon-
strated that the combination of CSP, MTX, and PSE was
m o re effective in preventing acute GVHD than the combina-
tion of CSP and PSE without MTX in a selected group of
optimal bone marrow transplantation (BMT) candidates, ie,
those in early stages of their leukemia [11]. 
Based on these results, we decided to perf o rm a pro s p e c-
tive randomized double-blind study to test this regimen of
C S P, MTX, and PSE compared with the standard widely
used regimen of CSP and MTX. The regimen of CSP was
identical in both arms; however, in the 3-drug arm, 3 doses
of MTX were administered on days 1, 3, and 6, whereas the
2 - d rug regimen used 4 doses of MTX on days 1, 3, 6, and 11. 
PATIENTS AND METHODS
Pa t i e n t s
All clinical protocols were approved by the Institutional
Review Boards at Stanford University Medical Center (Stan-
f o rd, CA), City of Hope National Medical Center (Duart e ,
CA), and Duke University Medical Center (Durham, NC).
The risks and benefits of the treatment regimens were
explained in detail to each patient during at least 2 outpatient
visits and again on the day of admission. Written inform e d
consent was obtained from all patients and, if the patient was
a minor, from a parent or guardian. Between 1992 and April
1998, 193 patients were entered into this trial. Five patients
w e re not evaluable for GVHD (they died between days 19
and 29 before engraftment: 3 of multiorgan failure, 1 of graft
f a i l u re, and 1 of diffuse alveolar hemorrhage) but were
included in the toxicity analyses, and 2 patients were deemed
ineligible (abnormal pretransplantation liver function tests
and the use of a diff e rent pre p a r a t o ry regimen). The re s u l t s
p resented are based on 186 evaluable patients. To be eligible
for the study, patients had to receive a bone marrow graft
f rom a histocompatible sibling donor for the treatment of
acute leukemia in first or second remission or first relapse or
c h ronic myelogenous leukemia in first or second chro n i c
phase or accelerated phase. Patient characteristics are
described in Table 1. Patients were well balanced in terms of
disease and stage, age, donor- recipient sex, and donor parity.
P re p a r a t o r y Regimens
The pre p a r a t o ry regimen was fractionated total-body
irradiation (fTBI) and etoposide in all but 13 patients, who
received fTBI and cyclophosphamide (7 in the 3-drug regi-
men; 6 in the 2-drug regimen). fTBI consisted of 1320 cGy
given in 11 fractions on day –7 through –4. Etoposide was
given intravenously as a single dose of 60 mg/kg over 4 hours
on day –3 [12]. Cyclophosphamide was given at a dose of
60 mg/kg/day over 1 hour on days –3 and –2. All patients
received bone marrow only, infused on day 0. 
GVHD Pr o p hy l a x i s
All patients received CSP by continuous intravenous
infusion with a loading dose starting on day –2 (Figure 1).
S e rum CSP concentrations were measured 3 times a week
by immunoassay (TDx System; Abbott Laboratories, Abbott
Park, IL). The patients were randomized to receive either
CSP/MTX/PSE or CSP/MTX. Patients randomized to the
3-drug group received a placebo on day 11 instead of MTX.
Patients randomized to the 2-drug group received a placebo
injection instead of PSE and an oral placebo tablet (sodium
bicarbonate) after they were able to take oral medication.
The placebo was taken through day 42, at which time the
patients were taken off placebo if on the 2-drug arm or con-
tinued on PSE as planned on the 3-drug arm. The random-
ization was blinded to all investigators and was known only
to the data management group and the pharmacist. 
GVHD Grading 
Acute GVHD was graded uniformly by clinical investi-
gators at the 3 study centers according to previously defined
criteria [13]. Retrospective chart reviews were also per-
formed by 1 independent investigator at the end of the trial.
All patients with a rash suggestive of GVHD underwent a
Table 1. Characteristics of Evaluable Patients*
CSP/MTX CSP/PSE/MTX P
No. of patients 96 90
Disease
Chronic myelogenous leukemia
CP1 39 (41) 36 (40) .97 †
Beyond CP1 5 (5) 7 (8)
Acute myelogenous leukemia
CR1 23 (24) 19 (21)
Beyond CR1 8 (8) 9 (10)
Acute lymphoblastic leukemia
CR1 12 (13) 10 (11)
Beyond CR1 9 (9) 9 (10)
Median age in years (range) 34.5 (1-50) 34.5 (2-49) .78 ‡
Donor-recipient sex
Match 51 (53) 45 (50) .77 †
Mismatch 45 (47) 45 (50)
Donor-recipient sex and parity
Nonparous F/F 6 (6) 3 (3) .61 †
Nonparous F/M 6 (6) 7 (8)
Parous F/F 8 (8) 12 (13)
Parous F/M 15 (16) 9 (10)
M/F 20 (21) 22 (24)
M/M 36 (38) 30 (33)
Unknown parity F/F 1 (1) 0 (0)
Unknown parity F/M 4 (4) 7 (8)
*Data are n (%) unless otherwise indicated. CP1 indicates first chronic phase;
CR1, first complete remission. 
†Fisher exact test.
‡Wilcoxon rank sum test.
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skin biopsy to document involvement with GVHD. Biopsies
of the liver or gut were perf o rmed as clinically indicated;
h o w e v e r, the ultimate grading was based on the clinical
signs and symptoms.
Dose Adjustment
If a patient developed clinical acute GVHD, the investi-
gators could place the patient on PSE (intravenous form u l a-
tion) at 1 mg/kg for up to 3 days while the skin or tissue
biopsy was obtained to document GVHD histologically. If
the biopsy did not confirm the diagnosis, the investigators
could resume the PSE/placebo administration. If the diagno-
sis was confirmed, the code was broken. If the patient was not
on the PSE-containing arm (ie, had been taking placebo),
PSE was continued at 1 mg/kg; if the patient was already on
PSE, the dose was increased to 2 mg/kg. The amount of each
d rug actually administered was determined by a review of
re c o rds and expressed as a percentage of planned doses. 
S u p p o rt i v e Care
All patients were hospitalized in private rooms with
high-efficiency particulate air filtration systems. Strict hand
washing was implemented with all patients. Broad-spectrum
antibiotics were used to treat initial episodes of fever, and
beginning on day 1, low-dose amphotericin B (0.15 mg/kg)
was given to all patients as prophylaxis for fungal infections
[14]. All blood products were irradiated at 2500 cGy. All
patients received intravenous immunoglobulins every other
week at a dose of 500 mg/kg. Patients who were seropositive
for cytomegalovirus or received bone marrow from a CMV-
seropositive donor were screened weekly for CMV antigen
and treated with preemptive ganciclovir if the CMV antigen
was detected [15]. Hematopoietic growth factors were not
routinely used in these patients.
Statistical Anal y s e s
T h roughout this study, patients were monitored by a
Data and Safety Monitoring Board at pre d e fined interv a l s .
This committee was led by the biostatistics group of the
p a rticipating centers and included 2 physicians not associ-
ated with the trial. The patient accrual goal was based on a
15% incidence of acute GVHD in the 3-drug arm com-
pared with 30% in the 2-drug arm. At the initiation of the
trial, 3 interim analyses were planned. At the second interim
analysis, after 186 patients had been registered, the Data and
Safety Monitoring Board conducted a Monte Carlo simula-
tion based on the current accrual and incidence of GVHD
in each of the 2 treatment arms. The conclusion from this
analysis suggested that further accrual would not achieve the
initially projected end point. There f o re, the study was
closed to further accrual and the results were analyzed.
Patient characteristics and outcomes in the 2 tre a t m e n t
g roups were compared by Fisher exact test and Wi l c o x o n
rank sum test. The significance testing of chronic GVHD
was performed using Pearson chi-square test. The Kaplan-
Meier method was used to estimate the probabilities of sur-
vival, relapse, and acute GVHD over time. The 2 study
groups were compared using log rank statistic [16].
RESULTS
Drug Administration
Both groups of patients had similar median serum concen-
trations of CSP. The median administered dose of MTX was
Day Dose Route
Cyclosporine –2 to 3 5 mg/kg IV q.d. over 20 hours
4 to 14 3 mg/kg IV q.d. over 20 hours
15 to 35 3.75 mg/kg IV q.d. over 20 hours
36 to 83 5 mg/kg p.o. b.i.d.
84 to 97 4 mg/kg p.o. b.i.d.
98 to 119 3 mg/kg p.o. b.i.d.
120 to 180 2 mg/kg p.o. b.i.d.
≥181 off
Methotrexate 1 15 mg/m 2 IV
3 10 mg/m 2 IV
6 10 mg/m 2 IV
11 10 mg/m 2 IV*
Methylprednisolone (IV)/prednisone (p.o.)
7 to 14 0.25 mg/kg IV b.i.d.
15 to 28 0.5 mg/kg IV b.i.d.
29 to 42 0.4 mg/kg p.o. b.i.d.
43 to 56 0.25 mg/kg p.o. b.i.d.
57 to 119 0.1 mg/kg p.o. b.i.d.
120 to 180 0.1 mg/kg p.o. q.d.
≥181 off
Figure 1. Schema of the 2 prophylactic regimens. *Note that the day-11 methotrexate dose in the 3-drug arm was a placebo.
Table 2. Patients Receiving Target MTX Dose*
CSP/MTX CSP/MTX/PSE
No. of patients 96 90
Day 1 93 (97) 85 (94)
Day 3 93 (97) 87 (97)
Day 6 83 (86) 77 (86)
Day 11 55 (57) 58 (64) †
*Data are n (%). 
†Placebo.
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100% of the planned dose. Of the patients in the 2-drug arm ,
90% received the day 1, 3, and 6 doses of MTX and 57%
received the day 11 dose (Table 2). All patients received the
t a rget doses of PSE (intravenous or oral) except patients who
developed acute GVHD, who received higher doses of PSE. 
E n g r a f t m e n t
All 186 patients experienced engraftment with donor
cells, according to assays using restriction fragment length
polymorphism or other suitable genetic markers. The
median time to myeloid re c o v e ry (500 granulocytes/µL)
was 19 days in the 3-drug arm compared with 21 days in
the 2-drug arm (P = .0001). The time to platelet transfusion
independence (>25,000 platelets/µL sustained for 3 days)
was 27 days for the 3-drug group and 30 days for the 2-d ru g
g roup (P = .67). 
G r a f t - V ersus-Host Disease
The incidence of grades II-IV acute GVHD was 20%
(95% confidence interval [CI] 12-28) for the 2-drug re g i-
men compared with 18% (CI 10-26) for the 3-drug regimen
(P = .60) in an intent-to-treat analysis. Although the total
incidence of acute GVHD was not significantly diff e re n t ,
the use of PSE seemed to delay the onset of GVHD (Fig-
u re 2). Patients receiving CSP and MTX had a median
onset of acute GVHD at 22 days (range 12-90) compare d
with 40.5 days (range 7-95) for those who also received PSE
(P = .02). It is important to note that with a follow-up of
0.7 to 6.0 years, the rates of chronic GVHD (limited and
extensive) were also equivalent between the 2 tre a t m e n t
arms (Table 3), 45% and 43%, respectively.
Figure 2. Incidence of onset of grade II to IV acute graft-versus-host disease (AGVHD) (P = .60).
Table 3. Graft-Versus-Host Disease (GVHD) Outcome*
CSP/MTX CSP/MTX/PSE P
No. of patients 96 90
Median days to 22 (12-90) 40.5 (7-95) . 0 2 †
acute GVHD (range) (n = 19) (n = 16)
Acute GVHD
Grade 0 58 (60) 60 (67)
Grade 1 19 (20) 14 (16)
Grade 2 9 (9) 9 (10)
Grade 3 5 (5) 1 (1)
Grade 4 5 (5) 6 (7)
Grade 0-1 77 (80) 74 (82) 0 . 7 3 ‡
Grade 2-4 19 (20) 16 (18)
Chronic GVHD 
N o n e 53 (55) 51 (57) 0 . 3 9 ‡
Limited 12 (13) 6 (7)
Extensive 31 (32) 33 (37)
*Data are n (%) unless otherwise indicated. For CGVHD significance testing
between arms, “limited” and “extensive” were combined as “yes” (2 × 2 table). 
†Wilcoxon rank sum test. 
‡Pearson chi-square test.
Table 4. Treatment Toxicities*
CSP/MTX CSP/MTX/PSE P
No. of patients 96 90
Mucositis (days of morphine 
d r i p ) †
Maximum 48 43 .33 ‡
Third quartile 25 23
Median 19 18
First quartile 15 15
Minimum 00 00
Peak creatinine (mg/dL) 1.8 (0.6-7.6) 1.8 (0.4-6.2) .30 ‡
over 100 days
Peak bilirubin (mg/dL) 2.9 (0.8-56) 2.8 (0.6-45) .90 ‡
over 100 days
Peak alkaline phosphatase 194.5 (61-1339) 146 (56-1271) . 0 0 2 ‡
(mg/dL) over 100 days
Peak AST (U/L) 102 (40-3711) 106 (25-662) .76 ‡
over 100 days
Peak ALT (U/L) 149.5 (29-3154) 232 (29-2030) .01 ‡
over 100 days
*Data are median (range) unless otherwise indicated. AST indicates aspartate
transaminase; ALT, alanine transaminase. 
†One patient from each group had missing mucositis data. 
‡Wilcoxon rank sum test.
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Tox i c i t y
Table 4 demonstrates the toxicity associated with these
2 regimens over the first 100 days after allografting. There
was no diff e rence in the overall incidence of mucositis
between the 2 regimens in spite of 1 arm receiving 4 versus
3 doses of MTX. The median peak serum creatinine and
b i l i rubin levels were likewise similar between the 2 tre a t-
ment arms. There was a higher median peak alkaline phos-
phatase level with the 2-drug regimen but higher median
alanine transaminase with the 3-drug regimen.
I n fe c t i o n s
Infection data were collected prospectively and corrobo-
rated with a retrospective review in a blinded fashion. The
data collected reflect any infection from the time of admis-
sion until 1 year after transplantation. Table 5 summarizes
the overall incidence of bacterial, viral, fungal, and other
infections. As demonstrated in Table 5, the incidence of
infectious complications was not significantly diff e re n t
between the 2 groups, although the 3-drug group tended to
have fewer infections. Of note, the addition of PSE did not
result in a higher incidence of fungal infections.
Reasons for Removal From Study
Table 6 details the reasons patients went off the study
d rug within the first 42 days, excluding death as an end
point. The results from this analysis demonstrate that a
higher number of patients withdrew from the study dru g
for acute GVHD in the 2-drug versus the 3-drug re g i m e n
(16 versus 5 patients, P = .02). More o v e r, there was a
t rend toward a higher incidence of diffuse alveolar hemor-
rhage in those patients not receiving PSE as part of
GVHD prophylaxis (8 versus 3, P = .22). The other causes
for  removal from the study were equally distributed
between the 2 gro u p s .
Treatment Outcome
As of July 15, 1999, estimated 2-year overall survival was
65% for those receiving CSP/MTX/PSE and 72% for those
receiving CSP/MTX (P = .10), with a relapse rate of 15%
for the CSP/MTX/PSE arm and 12% for the CSP/MTX
a rm (P = .83). There was no significant difference in overall
s u rvival, event-free survival, or time to relapse between the
2 groups (Figures 3, 4, and 5). Both groups of patients had a
rather favorable outcome from this procedure (Table 7).
DISCUSSION
This re p o rt describes our experience with a pro s p e c-
tive double-blind randomized study for the prevention of
acute GVHD in patients undergoing allogeneic bone mar-
row transplantation for hematologic diseases. We com-
p a red the combination of CSP and MTX developed by the
Seattle group with the CSP, MTX, and PSE regimen we
had developed. The results of this study demonstrate that
the regimens are equally effective in the prevention of
acute GVHD. 
Table 5. Infectious Complications Between the 2 Treatment Groups*
CSP/MTX CSP/MTX/PSE
Documented Infections (n) Patients (n) Documented Infections (n) Patients (n)
Bacterial infections 112 56 88 48
Gram positive 52 35 44 34
Gram negative 44 30 36 23
Others 16 16 8 8
Viral infections 97 69 83 63
Cytomegalovirus 57 56 47 46
Herpes simplex 25 23 25 25
Herpes zoster 10 10 6 6
Varicella 1 1 0 0
Other 4 4 5 5
Fungal infections 16 16 15 13
Aspergillus 10 10 7 7
Candida 5 5 5 4
Other 1 1 3 3
Other infections † 3 3 1 1
*Includes 5 patients not evaluable for graft-versus-host disease. 
†Toxoplasmosis, Pneumocystis carinii, or Mycobacterium.
Table 6. Reasons for Discontinuing Assigned Therapy
CSP/MTX CSP/MTX/PSE Total
Graft-versus-host disease 16 5 21 
Diffuse alveolar hemorrhage 8 3 11
Adult respiratory distress syndrome 2 1 3
Lung disease 1 0 1
Rising bilirubin 1 0 1
Interstitial pneumonitis 0 1 1
Relapse 0 1 1
Mucositis/sepsis 1 0 1
Other toxicity 1 0 1 
PSE for placebo* 0 1 1
Wrong MTX dose 1 1 2
Refused MTX 1 0 1
Accidental unblind 1 0 1
Total 33 13 46 
*PSE was substituted for placebo when the patient was diagnosed with graft-
versus-host disease.
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The combination of CSP and MTX has been shown in
several studies to be more effective than single agents in the
p revention of acute GVHD. This regimen is the most
widely used combination for prophylaxis against acute
GVHD. The incidence of grade II to IV acute GVHD is
a p p roximately 35% [7,8], and the incidence of chro n i c
GVHD is approximately 40%. When PSE was added to this
regimen beginning on day 0, the incidence of acute GVHD
i n c reased,  possibly because of interf e rence with the
i m m u n o s u p p ressive action of MTX by the steroids [17].
The overall survival between those who received stero i d s
and those who did not was similar.
We had previously tested a regimen consisting of CSP,
3 doses of MTX, and PSE beginning on day 7 in a uniform
g roup of patients with leukemia [11]. These patients were
optimal candidates for allogeneic BMT. All were in first
complete remission of their acute leukemia or in first chro n i c
phase of chronic myeloid leukemia, and all received the same
p re p a r a t o ry regimen consisting of fTBI and etoposide. In
that study, we compared the 3-drug regimen to CSP and
PSE. The results demonstrated a low incidence of acute
GVHD of only 9% in patients receiving the 3 drugs. More-
o v e r, whereas the overall incidence of chronic GVHD was
a p p roximately 60%, the incidence of extensive chro n i c
GVHD was not excessive, resulting in an overall Karn o f s k y
p e rf o rmance status of at least 80% in the majority of
patients. The 3-drug combination as tested was not simply
the addition of steroids to the conventional 2-drug re g i m e n
of CSP and MTX; it used only 3 doses of MTX given on
days 1, 3, and 6 with the steroids beginning on day 7. MTX
was given for only 3 days because prior studies had suggested
that many patients were not able to receive the day 11 dose.
The present study demonstrates an equivalent inci-
dence of acute GVHD of 18% to 20% with either re g i-
men. The incidence of acute GVHD was higher than we
had predicted with the 3-drug regimen and lower than
p redicted with the standard CSP/MTX regimen based on
our experience and results published in the literature. The
Figure 3. Overall survival (OS) in the 2 treatment groups (P = .10).
Figure 4. Event-free survival (EFS) in the 2 treatment groups (P = .18).
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d i ff e rence in the incidence of acute GVHD using the 3-d ru g
regimen in this study and our previously published obser-
vations may be explained by diff e rences in patient popula-
tion. Whereas the previous study randomized only optimal
candidates, the current study allowed for patients with
m o re advanced leukemias. Other re p o rts have demon-
strated that advanced leukemia is an independent risk fac-
tor for acute GVHD [18]. There f o re, the higher incidence
of acute GVHD in this study was not surprising; the lower
incidence of acute GVHD with the 2-drug regimen was
unexpected, however. In this study, the majority of patients
received the target doses of MTX (nearly 90% received the
day 6 dose and 60% the day 11 dose), and dose re d u c t i o n s
in MTX on days 6 and 11 have been associated with a
higher incidence of acute GVHD. Most of the patients had
the later doses of MTX delayed for either severe mucositis
or azotemia. There f o re, the commitment of the investiga-
tors to deliver the target doses may have led to this lower
incidence of acute GVHD in the group re c e i v i n g
CSP/MTX compared with the published data. In the Seat-
tle experience, 26% of patients did not receive MTX at all
on day 11 [18]. The diff e rence between the ability to
deliver the full day 11 dose of MTX may explain the lower
incidence of acute GVHD in the 2-drug arm compare d
with previously published experience.
Although the overall incidence of acute GVHD
between the 2 arms was not diff e rent by day 100, there
w e re diff e rences within the first 100 days. The median
time to acute GVHD was 22 days for CSP/MTX compare d
with 40.5 days for CSP/MTX/PSE. More o v e r, as demon-
strated in Table 6, more patients in the CSP/MTX arm
c o m p a red with patients in the 3-drug arm went off the
study because of the development of acute GVHD. That
e ffect was only temporary, however, and by day 100, the
incidence of acute GVHD was similar (Figure 2). The
incidence of diffuse alveolar hemorrhage was also higher in
the patients receiving only CSP/MTX. These data hint at
the possibility that steroids will blunt the initial (possibly
c y t o k i n e - related) toxicity associated with high-dose radia-
tion and chemotherapy. 
The occurrence of acute GVHD also predicts the
development of chronic GVHD. There have been concern s
that the use of PSE may actually increase the incidence of
c h ronic GVHD. In this randomized study, we could not
detect a diff e rence in the incidence or severity of limited or
extensive chronic GVHD. Relapse rates were also similar in
the 2 groups of patients. The relatively low relapse rate
may be partly explained by the combination of the pre p a r a-
t o ry regimen with the incidence of chronic GVHD, ie,
graft-versus-leukemia eff e c t .
A previous re t rospective study from Seattle suggested
that there was an increased risk of infection in marrow trans-
plantation patients receiving PSE for GVHD prevention [18].
In our study, using an intent-to-treat analysis, we did not
detect any significant diff e rence in overall incidence or types
of infectious complications in the 2 treatment groups, with
m o re than 1 year of minimum follow-up. In fact, the overall
number of bacterial infections was lower in the patients on
PSE compared with those who did not receive PSE (Table 5).
It is not clear whether this comparable immunosuppression is
due to the delivery of day 11 MTX in the 2-drug arm or
whether the infectious prophylaxis measures have impro v e d
since the previously re p o rted Seattle experience. These
results suggest that the addition of PSE did not result in a
deleterious effect on infectious complications.
Figure 5. Probability of relapse in each of the treatment arms (P = .83).
Table 7. Treatment Outcomes*
CSP/MTX CSP/PSE/MTX P
No. of patients 96 90
Follow-up (months)
Total 28 (0.7-69) 25 (0.7-72) .64 †
Alive only 38 (14-69) 44 (9-72) .44 †
Patients alive ‡ 70 (72; 63-81) 54 (65; 55-75) .10 §
Leukemic recurrence § 11 (10; 2-22) 11 (15; 7-23) .83 §
*Data are median (range) or n (%; 95% CI). 
†Wilcoxon rank sum test.
‡Kaplan-Meier 2-year estimates.
§Log rank statistic.
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These results are also in contrast to a previous re p o rt
comparing the 2 regimens in which the 3-drug regimen was
associated with a lower incidence of acute GVHD, but
again, no difference in disease-free or overall survival [19].
D i ff e rences between these 2 studies may be secondary to
patient selection, numbers of patients enrolled, or diff e r-
ences in the grading of acute GVHD. Moreover, our study
blinded the methylprednisolone and the fourth dose of
MTX to prevent potential investigator biases.
In conclusion, our study demonstrates that both pro-
phylactic regimens are associated with acceptable rates of
acute GVHD. Likewise, the tre a t m e n t - related toxicities,
relapse rate, disease-free and overall survival, and incidence
of chronic GVHD were not statistically diff e rent. There
was a suggestion that the addition of steroids may have been
associated with a lower incidence of early complications. 
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